Luxembourg, 23rd November
Ai Mediq S.A. is pleased to announce the new stage of scientific cooperation with the Universitätsklinikum Hamburg-Eppendorf (UKE). Together with Dr. Sina Cathérine Rosenkranz we will be looking into potential perspectives of Interval Hypoxic Therapy in the treatment of multiple sclerosis. The pilot clinical trial will be conducted by the Institut für Neuroimmunologie und Multiple Sklerose (INIMS) and will be performed under the supervision of Prof.Dr.med. Manuel Friese und Prof. Dr. Christoph Heesen.
We at Ai Mediq are always open to the new ideas and eagerly support new research for Interval Hypoxic therapy by any means possible. We expect the first outcomes in the second part 2021 and wish all the success to our colleagues.
Dr. Rosenkranz works as a postdoctoral researcher at the Institute of Neuroimmunology and Multiple Sclerosis (INIMS). Her work focuses on the role of mitochondria alterations during multiple sclerosis and the molecular basis of neuroprotective behavioural interventions, such as exercise and hypoxia. She is an author of more than 10 publications in the field of multiple sclerosis.
Multiple sclerosis is the most common immune-mediated disorder affecting the central nervous system. In 2015, about 2.3 million people were affected globally, with rates varying widely in different regions and among different populations. More details on Multiples Sclerosis can be found on Wikipedia article that was used as a source for this paragraph.